Filing Flows › Zevra Therapeutics (ZVRA) › Q3 2026 › vs Q3 2025
Zevra Therapeutics (ZVRA) Q3 2026 vs Q3 2025 (year over year)
Zevra Therapeutics's revenue rose $11.7M (+45%) from $26.1M in Q3 2025 to $37.8M in Q3 2026. Operating margin 30.7% against 15.9% (+14.8 pts).
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 30.7% | 15.9% | +14.8 pts |
| Net margin | 50.9% | -2.1% | +53.0 pts |
| Free cash flow margin | 26.0% | 15.9% | +10.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $37.8M | $26.1M | $11.7M | +45% |
| Other income, net | $8.1M | −$5.1M | $13.3M | — |
| Operating profit | $11.6M | $4.1M | $7.4M | +180% |
| Costs & expenses | $26.2M | $21.9M | $4.3M | +19% |
| Pre-tax earnings | $19.7M | −$977K | $20.7M | — |
| Cost of revenue | $1.8M | $1.2M | $556K | +45% |
| Research & development | $4.9M | $3.4M | $1.5M | +44% |
| SG&A | $19.1M | $16.9M | $2.2M | +13% |
| Other operating costs | $315K | $315K | $0 | 0% |
| Net earnings | $19.2M | −$544K | $19.8M | — |
| Income tax | $510K | −$433K | $943K | — |
| Depreciation & amortization | $378K | $392K | −$14K | -4% |
| Share-based compensation | $2.7M | $2.8M | −$99K | -4% |
| Working capital & other | $12.2M | −$2.1M | $14.3M | — |
| Operating cash flow | $10.0M | $4.7M | $5.3M | +113% |
| Free cash flow (OCF − capex) | $9.8M | $4.2M | $5.7M | +136% |
| Capital expenditures | $238K | $554K | −$316K | -57% |
Questions
How much did Zevra Therapeutics's revenue grow year over year in Q3 2026?
Zevra Therapeutics's revenue rose $11.7M (+45%) from $26.1M in Q3 2025 to $37.8M in Q3 2026. Operating margin 30.7% against 15.9% (+14.8 pts).